var data={"title":"Naloxone: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Naloxone: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6623?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=naloxone-drug-information\" class=\"drug drug_general\">see &quot;Naloxone: Drug information&quot;</a> and <a href=\"topic.htm?path=naloxone-patient-drug-information\" class=\"drug drug_patient\">see &quot;Naloxone: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50353046\" class=\"block spa drugH1Div\"><span class=\"drugH1\">Special Alerts</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Narcan Interim Order to Expire</span>\n      <span class=\"collapsible-date\">July 2017</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">Health Canada is advising health care providers that the Canadian authorized version of Narcan will transition onto the market by July 5, 2017. In July 2016, an Interim Order was issued that permitted the importation, sale, and distribution of Narcan approved in the United States for 1 year. On July 5, 2017, the Interim Order will expire. Product obtained under the Interim Order can continue to be used, but new orders will be for the Canadian-authorized Narcan product. There will be a period of time in which both products will be available.</p>\n        <p style=\"text-indent:0em;\">For further information, visit http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2017/63784a-eng.php.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25063978\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Evzio;</li>\n      <li>Narcan</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2980444\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Naloxone Hydrochloride Injection;</li>\n      <li>Naloxone Hydrochloride Injection USP</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1054265\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antidote for Narcotic Agonists</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11443895\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Not recommended as part of initial resuscitative efforts in the delivery room for neonates with respiratory depression; support ventilation to improve oxygenation and heart rate (Kattwinkel 2010):</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Opioid intoxication/overdose (full reversal):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV (preferred), Intraosseous: <b>Note: </b>May be administered IM, SubQ, or E.T., but onset of action may be delayed, especially if patient has poor perfusion; E.T. preferred if IV/Intraosseous route not available; doses may need to be repeated: 0.1 mg/kg/dose; repeat every 2 to 3 minutes if needed; monitor closely; may need to repeat doses (eg, every 20 to 60 minutes) if duration of action of opioid is longer than naloxone (PALS [Kleinman 2010])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">E.T.: Optimal endotracheal dose unknown; current expert recommendations are 2 to 3 times the IV dose (PALS [Kleinman 2010])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM: Evzio (auto-injector): 0.4 mg or 2 mg (contents of 1 auto-injector) as a single dose; may repeat every 2 to 3 minutes if needed until emergency medical assistance becomes available. <b>Note:</b> IM absorption may be delayed or erratic; in neonates with known or suspected exposure to maternal opioid use, consider using another form of naloxone (eg, parenteral formulation) to allow dosing according to weight and titration to effect.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intranasal: Narcan Nasal Spray: 4 mg (contents of 1 nasal spray) as a single dose; may repeat every 2 to 3 minutes in alternating nostrils if needed until medical assistance becomes available. <b>Note:</b> Intranasal absorption may be delayed or erratic; abrupt precipitation of opioid withdrawal symptoms may occur; in neonates with known or suspected exposure to maternal opioid use, consider using another form of naloxone (eg, parenteral formulation) to allow dosing according to weight and titration to effect.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Opioid-induced depression:</b> Manufacturer's labeling (parenteral formulation): IV, IM, SubQ: Initial: Usual: 0.01 mg/kg/dose; <b>Note:</b> This dose is <b>one-tenth</b> of the dose used for neonatal opioid intoxication (full reversal); may repeat every 2 to 3 minutes as needed based on response; may need to repeat every 1 to 2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Reversal of respiratory depression from therapeutic opioid dosing: </b>IV: 0.001 to 0.005 mg/kg/dose; titrate to effect (PALS [Kleinman 2010]); AAP recommends a wider dosage range of 0.001 to 0.015 mg/kg/dose (Hegenbarth 2008)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1054259\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=naloxone-drug-information\" class=\"drug drug_general\">see &quot;Naloxone: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Opioid intoxication/overdose (full reversal):</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV (preferred), Intraosseous: <b>Note:</b> May be administered IM, SubQ, or E.T., but onset of action may be delayed, especially if patient has poor perfusion; E.T. preferred if IV/Intraosseous route not available; doses may need to be repeated (Hegenbarth 2008; PALS [Kleinman 2010]).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children &lt;5 years or &le;20 kg: 0.1 mg/kg/dose; repeat every 2 to 3 minutes if needed; monitor closely; may need to repeat doses (eg, every 20 to 60 minutes) if duration of action of opioid is longer than naloxone</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &ge;5 years or &gt;20 kg and Adolescents: 2 mg/dose; if no response, repeat every 2 to 3 minutes; monitor closely; may need to repeat doses (eg, every 20 to 60 minutes) if duration of action of opioid is longer than naloxone</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">E.T.: Infants, Children, and Adolescents: Optimal endotracheal dose unknown; current expert recommendations are 2 to 3 times the IV dose (PALS [Kleinman 2010]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IM, SubQ: <b>Note:</b> IM or SubQ absorption may be delayed or erratic.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Auto-injector:</i> Evzio: Infants, Children, and Adolescents: 0.4 mg or 2 mg (contents of 1 auto-injector) as a single dose; may repeat every 2 to 3 minutes if needed until emergency medical assistance becomes available.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Parenteral formulation </i>(Hegenbarth 2008): IM, SubQ:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Infants and Children &lt;5 years or &lt;20 kg: 0.1 mg/kg/dose; repeat every 2 to 3 minutes if needed; monitor closely; may need to repeat doses (eg, every 20 to 60 minutes) if duration of action of opioid is longer than naloxone</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Children &ge;5 years or &ge;20 kg and Adolescents: 2 mg/dose; if no response, repeat every 2 to 3 minutes; monitor closely; may need to repeat doses (eg, every 20 to 60 minutes) if duration of action of opioid is longer than naloxone</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intranasal: <b>Note:</b> Onset of action is slightly delayed compared to IM or IV routes (Barton 2005; Kelly 2005).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Narcan Nasal Spray: Infants, Children, and Adolescents: 4 mg (contents of 1 nasal spray) as a single dose; may repeat every 2 to 3 minutes in alternating nostrils if needed until medical assistance becomes available</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Alternate dosing: Parenteral formulation (1 mg/mL injection) for intranasal administration: Adolescents &ge;13 years: 2 mg (1 mg per nostril) (Barton 2005; Kelly 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous IV infusion: Limited data available: Infants, Children, and Adolescents: 24 to 40 <b>mcg</b>/kg/<b>hour</b> has been reported (Gourlay 1983; Lewis 1984; Tenenbein 1984). Doses as low as 2.5 <b>mcg</b>/kg/<b>hour</b> have been reported in adults and a dose of 160 <b>mcg</b>/kg/<b>hour</b> was reported in one neonate (Tenenbein 1984). If continuous infusion is required, calculate the initial dosage/<b>hour</b> based on the effective intermittent dose used and duration of adequate response seen (Tenenbein 1984) <b>or</b> use two-thirds (<sup>2</sup>/<sub>3</sub>) of the initial effective naloxone bolus given as the hourly infusion (Perry 1996); titrate dose; <b>Note:</b> The infusion should be discontinued by reducing the infusion rate in decrements of 25%; closely monitor the patient (eg, pulse oximetry and respiratory rate) after each adjustment and after discontinuation of the infusion for recurrence of opioid-induced respiratory depression (Perry 1996).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Reversal of respiratory depression from therapeutic opioid dosing:</b> Infants, Children, and Adolescents: IV: 0.001 to 0.005 mg/kg/dose; titrate to effect (PALS [Kleinman 2010]); AAP recommends a wider dosage range of 0.001 to 0.015 mg/kg/dose (Hegenbarth 2008); manufacturer's labeling suggests repeat doses may be given every 2 to 3 minutes as needed based on response</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Opioid-induced pruritus:</b> Limited data available:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Prevention: Children &ge;6 years and Adolescents &le;17 years: Continuous IV infusion: 0.25 <b>mcg</b>/kg/<b>hour</b> was used in a double-blind, prospective, randomized, placebo-controlled study (n=20) which showed lower incidence and severity of opioid-induced side effects (ie, pruritus, nausea) without a loss of pain control (Maxwell 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Treatment: Children &ge;3 years and Adolescents: Continuous IV infusion: Initial: 2 <b>mcg</b>/kg/<b>hour</b>; if pruritus continues, may titrate by 0.5 <b>mcg</b>/kg/<b>hour</b> every few hours; dosing based on a retrospective study (n=30, age range: 3 to 20 years) with a reported mean (&plusmn;SD) dose of 2.3 &plusmn; 0.68 <b>mcg</b>/kg/<b>hour</b>; monitor closely; doses &ge;3 <b>mcg</b>/kg/<b>hour</b> may increase risk for loss of pain control and patients may require an increase in opioid dose (Vrchoticky 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Note:</b> Available routes of administration include IV (preferred), IM, SubQ, and intranasal; other available routes include inhalation via nebulization and intraosseous. Endotracheal administration is the least desirable and is supported by only anecdotal evidence (case report) (AHA [Neumar 2010]):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Opioid overdose: Note:</b> For the initial treatment of an opioid-associated life-threatening emergency, the American Heart Association recommends, after initiation of CPR, the use of intranasal or IM naloxone with repeat doses as needed. If there is an initial patient response (ie, purposeful movement, regular breathing, moan, or other response) but the patient then stops responding, begin CPR and repeat naloxone dose. If no initial response, continue CPR and use AED as appropriate (AHA [Lavonas 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV, IM, SubQ: Initial: 0.4 to 2 mg; may need to repeat doses every 2 to 3 minutes. A lower initial dose (0.1 to 0.2 mg) should be considered for patients with opioid dependence to avoid acute withdrawal or if there are concerns regarding concurrent stimulant overdose (Mokhlesi 2003). After reversal, may need to readminister dose(s) at a later interval (ie, 20 to 60 minutes) depending on type/duration of opioid. If no response is observed after 10 mg total, consider other causes of respiratory depression. <b>Note: </b>May also be given endotracheally as 2 to 2.5 times the initial IV dose (ie, 0.8 to 5 mg) (AHA [Neumar 2010]).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IM, SubQ (Evzio): 0.4 mg or 2 mg (contents of 1 auto-injector) as a single dose; may repeat every 2 to 3 minutes until emergency medical assistance becomes available</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Continuous IV infusion: <b>Note:</b> For use with exposures to long-acting opioids (eg, methadone), sustained release product, and symptomatic body packers after initial naloxone response. Calculate dosage/hour based on effective intermittent dose used and duration of adequate response seen (Tenenbein 1984) <b>or</b> use two-thirds (<sup>2</sup>/<sub>3</sub>) of the initial effective naloxone bolus on an hourly basis (typically 0.25 to 6.25 mg/hour); one-half (<sup>1</sup>/<sub>2</sub>) of the initial bolus dose should be readministered 15 minutes after initiation of the continuous infusion to prevent a drop in naloxone levels; adjust infusion rate as needed to assure adequate ventilation and prevent withdrawal symptoms (Goldfrank 1986).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Inhalation via nebulization: 2 mg; may repeat. Switch to IV or IM administration when possible (Weber 2012). <b>Note:</b> This administration method is not included in the AHA recommendations for initial management of opioid-associated life-threatening emergency (AHA [Lavonas 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intranasal: <b>Note:</b> Onset of action is slightly delayed compared to IM or IV routes (Kelly 2005; Robertson 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Narcan Nasal Spray: 4 mg (contents of 1 nasal spray) as a single dose; may repeat every 2 to 3 minutes in alternating nostrils until medical assistance becomes available</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Alternate dosing: 2 mg (1 mg per nostril) using generic injectable solution (with a mucosal atomization device); may repeat in 3 to 5 minutes if respiratory depression persists (AHA [Lavonas 2015]; AHA [Vanden Hoek 2010]; Kelly 2005; Robertson 2009; Walley 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Reversal of respiratory depression with therapeutic opioid doses:</b> IV: Initial: 0.02 to 0.2 mg; titrate to avoid profound withdrawal, seizures, arrhythmias, or severe pain (AHA [Lavonas 2015]; APS 2008; Doyon 2010). <b>Note:</b> May be given endotracheally as 2 to 2.5 times the initial IV dose (ie, 0.04 to 0.5 mg) (AHA [Neumar 2010]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Continuous IV infusion:</i> <b>Note:</b> For use with exposures to long-acting opioids (eg, methadone) or sustained release products. Calculate dosage/hour based on effective intermittent dose used and duration of adequate response seen (Tenenbein 1984) <b>or</b> use two-thirds (<sup>2</sup>/<sub>3</sub>) of the initial effective naloxone bolus on an hourly basis (typically 0.2 to 0.6 mg/hour); one-half (<sup>1</sup>/<sub>2</sub>) of the initial bolus dose should be readministered 15 minutes after initiation of the continuous infusion to prevent a drop in naloxone levels; adjust infusion rate as needed to assure adequate ventilation and prevent withdrawal symptoms (Goldfrank 1986)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Postoperative opioid reversal:</b> IV: 0.1 to 0.2 mg every 2 to 3 minutes until desired response (adequate ventilation and alertness without significant pain). <b>Note:</b> Repeat doses may be needed within 1- to 2-hour intervals depending on type, dose, and timing of the last dose of opioid administered.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199436\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Liquid, Nasal: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Narcan: 4 mg/0.1 mL (1 ea) [contains benzalkonium chloride, edetate disodium]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.4 mg/mL (1 mL); 4 mg/10 mL (10 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Auto-injector, Injection, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Evzio: 0.4 mg/0.4 mL (0.4 mL); 2 mg/0.4 mL (0.4 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Cartridge, Injection, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.4 mg/mL (1 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Prefilled Syringe, Injection, as hydrochloride [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 2 mg/2 mL (2 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199421\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1054269\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endotracheal: Dilute with NS prior to administration; follow with a flush &ge;5 mL of NS and 5 consecutive positive-pressure ventilations (PALS [Kleinman 2010])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Inhalation via nebulization: Adults: Dilute with NS and administer via nebulizer face mask (Mycyk 2003; Weber 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intranasal:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Narcan Nasal Spray: Administer initial dose as soon as possible. Do not prime or test the device prior to administration. Administer in alternating nostrils with each dose. Place the patient in the supine position and provide support to the back of the neck to allow the head to tilt back. Following administration, turn the patient on their side (recovery position). Each container contains a single intranasal spray; do not reuse; if repeat administration is necessary, a new container must be used.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Parenteral formulation for intranasal use: Adolescents and Adults: Administer total dose equally divided into each nostril using a mucosal atomizer device (MAD) (AHA [Vanden Hoek 2010]; Kelly 2005; Robertson 2009). If a MAD is not available, the solution may be sprayed into the nares without a MAD; however, a significant amount of drug may be lost likely due to swallowing and subsequent first-pass metabolism (Dowling 2008; Robinson 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV push: Administer over 30 seconds as undiluted preparation. May also be diluted and administer slow IV push (APS 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Continuous IV infusion: Dilute in NS or D5W prior to administering as continuous IV infusion</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM, Intraosseous, SubQ: May administer IM, Intraosseous, or SubQ if unable to obtain IV access. <b>Note:</b> IM or SubQ administration in pediatric patients, hypotensive patients, or patients with peripheral vasoconstriction or hypoperfusion may result in erratic or delayed absorption.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Auto-injector: Evzio: For IM or SubQ use only. Intended for buddy administration; the person administering the medication should follow the printed instructions on the device or the electronic voice instructions coming from the speaker on the device. If the voice instruction system does not operate properly, the device will still deliver the intended dose of naloxone when properly administered. Administer IM or SubQ into the anterolateral aspect of the thigh; may be injected through clothing. When being administered to infants &lt;1 year of age, the thigh muscle should be pinched during administration. Following proper administration, a red indicator appears in the viewing window; the needle is not visible before, during, or after the injection. Do not replace red safety guard for any reason. Patients who received naloxone in the out-of-hospital setting should seek immediate emergency medical assistance after the first dose due to the likelihood that respiratory and/or central nervous system depression will return. Repeat doses may be required until emergency medical assistance becomes available; a new device must be used as each device contains a single dose of naloxone.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199454\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Solution, injection: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Protect from light. Use IV infusion in NS or D5W within 24 hours of preparation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Solution, auto-injector: Store at 15&deg;C to 25&deg;C (59&deg;F to 77&deg;F); excursions are permitted between 4&deg;C and 40&deg;C (39&deg;F and 104&deg;F). Store in the outer case provided.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Solution, nasal spray: Store at 15&deg;C to 25&deg;C (59&deg;F to 77&deg;F); excursions are permitted between 4&deg;C and 40&deg;C (39&deg;F and 104&deg;F). Do not freeze. Protect from light.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1054268\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Injection: Complete or partial reversal of opioid drug effects, including respiratory depression induced by natural and synthetic opioids; diagnosis and management of known or suspected acute opioid overdose (FDA approved in all ages); has also been used for the prevention and treatment of opioid-induced pruritus </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Auto-injector (Evzio): Emergency treatment of known or suspected opioid overdose as manifested by respiratory and/or CNS depression (FDA approved in all ages). Intended for immediate administration as emergency therapy in settings where opioids may be present; not a substitute for emergency medical care</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intranasal: Narcan Nasal Spray: Emergency treatment of known or suspected opioid overdose as manifested by respiratory and/or CNS depression (FDA approved in all ages). Intended for immediate administration as emergency therapy in settings where opioids may be present; not a substitute for emergency medical care</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199507\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Naloxone may be confused with Lanoxin, nalbuphine, naltrexone </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Narcan may be confused with Marcaine, Norcuron</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Narcan [multiple international markets] may be confused with Marcen brand name for ketazolam [Spain]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199504\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Flushing (parenteral), hypertension, hypotension, tachycardia, ventricular fibrillation, ventricular tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Agitation, body pain, brain disease, coma, confusion (parenteral), disorientation (parenteral), dizziness (parenteral), excessive crying (neonates), hallucination (parenteral), headache (nasal), hyperreflexia (neonates), irritability, nervousness, outbursts of anger (parenteral), paresthesia (parenteral), restlessness, seizure (neonates), shivering, tonic-clonic seizures (parenteral), withdrawal syndrome, yawning</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Diaphoresis, piloerection, xeroderma (nasal)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Hot flash (parenteral)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal cramps, constipation (nasal), diarrhea, nausea, toothache (nasal), vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Erythema at injection site (parenteral), injection site reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Muscle spasm (nasal), musculoskeletal pain (nasal), tremor, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Dry nose (nasal), dyspnea, hypoxia (parenteral), nasal congestion (nasal), nasal discomfort (pain; nasal), nasal mucosa swelling (nasal), pulmonary edema, respiratory depression (parenteral), rhinitis (nasal), rhinorrhea, sneezing</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199443\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to naloxone or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199425\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Acute opioid withdrawal: Administration of naloxone causes the release of catecholamines, which may precipitate acute withdrawal or unmask pain in those who regularly take opioids. Symptoms of acute withdrawal in opioid-dependent patients may include pain, tachycardia, hypertension, fever, sweating, abdominal cramps, diarrhea, nausea, vomiting, agitation, and irritability. In neonates born to mothers with opioid dependence, opioid withdrawal may be life-threatening and symptoms may include excessive crying, shrill cry, failure to feed, seizures, and hyperactive reflexes. In settings other than acute opioid overdose (eg, postoperative patients), carefully titrate the dose to reverse hypoventilation; do not fully awaken patient or reverse analgesic effect. The 2 mg nasal dose (off-label) is less likely to precipitate severe opioid withdrawal compared to the 4 mg dose; however, the 2 mg dose may not provide an adequate and timely reversal in patients who have been exposed to an overdose of a potent or very high dose of opioids.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease or in patients receiving medications with potential adverse cardiovascular effects (eg, hypotension, pulmonary edema or arrhythmias); pulmonary edema and cardiovascular instability, including ventricular fibrillation, have been reported in association with abrupt reversal when using opioid antagonists.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizures: Use caution in patients with history of seizures; avoid use in the treatment of meperidine-induced seizures.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Auto-injector: When administered to infants &lt;1 year of age, monitor the injection site for residual needle parts and signs of infection.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Addiction involving opioid use: To prevent overdose deaths, there are initiatives to dispense naloxone for self- or buddy-administration to patients at risk of opioid overdose (eg, recipients of high-dose opioids, suspected or confirmed history of illicit opioid use) and individuals likely to be present in an overdose situation (eg, family members of illicit drug users) (Albert 2011; Bennett 2011). Clinical practice guidelines recommend patients being treated for opioid use disorder should be given prescriptions for naloxone. Patients and family members/significant others should be trained in the use of naloxone in overdose (Kampman [ASAM 2015]). Evzio is indicated for emergency treatment. Needleless administration via nebulization and the intranasal route using the injectable solution (with a mucosal atomization device) by first responders and bystanders has also been described (Doe-Simkins 2009; Weber 2012). Needleless administration provides an alternative route of administration in patients with venous scarring due to illicit drug use (eg, heroin). There is a low incidence of death following naloxone reversal of opioid toxicity in patients who refuse transport to a healthcare facility (Wampler 2011). Nevertheless, patients who received naloxone in the out-of-hospital setting should seek immediate emergency medical assistance after the first dose due to the likelihood that respiratory and/or central nervous system depression will return.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Opioid overdose: Recurrence of respiratory and/or CNS depression is possible if the opioid involved is long-acting; continuously observe patients until there is no further risk of recurrent respiratory or CNS depression.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Partial opioid agonist and mixed opioid agonist/antagonist overdose: Reversal of partial opioid agonists or mixed opioid agonist/antagonists (eg, buprenorphine, pentazocine) may be incomplete and larger or repeat doses of naloxone may be required.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Postoperative reversal: Appropriate use: Excessive dosages should be avoided after use of opioids in surgery. Abrupt postoperative reversal may result in nausea, vomiting, sweating, tachycardia, hypertension, seizures, and other cardiovascular events (including pulmonary edema and arrhythmias).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299739\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199430\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12628&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Methylnaltrexone: May enhance the adverse/toxic effect of Opioid Antagonists. Specifically, the risk for opioid withdrawal may be increased.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naldemedine: Opioid Antagonists may enhance the adverse/toxic effect of Naldemedine. Specifically, the risk for opioid withdrawal may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naloxegol: Opioid Antagonists may enhance the adverse/toxic effect of Naloxegol. Specifically, the risk for opioid withdrawal may be increased. <i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199432\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (product-specific) (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199446\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were not observed in animal reproduction studies. Naloxone crosses the placenta and may precipitate opioid withdrawal in the fetus.  Naloxone is not recommended for use in pregnant women with opioid use disorder except in situations of life threatening overdose (Kampman [ASAM 2015]). Use to diagnose opioid dependence during pregnancy is contraindicated (ACOG 2012). In general, medications used as antidotes should take into consideration the health and prognosis of the mother; antidotes should be administered to pregnant women if there is a clear indication for use and should not be withheld because of fears of teratogenicity (Bailey 2003). Use caution in pregnant women with mild-to-moderate hypertension during labor; severe hypertension may occur.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1054264\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Respiratory rate, heart rate, blood pressure, temperature, level of consciousness, ABGs, or pulse oximetry. Auto-injector: Evzio: When administered to infants &lt;1 year of age, monitor the injection site for residual needle parts and signs of infection.     </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199424\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Pure opioid antagonist that competes and displaces opioids at opioid receptor sites</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199442\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Endotracheal, IM, SubQ: 2 to 5 minutes; Inhalation via nebulization: ~5 minutes (Mycyk 2003); Intranasal: ~8 to 13 minutes (Kelly 2005; Robertson 2009); IV: ~2 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: ~30 to 120 minutes depending on route of administration; IV has a shorter duration of action than IM administration; since naloxone's action is shorter than that of most opioids, repeated doses are usually needed</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Intranasal, IM, SubQ: Pediatric patients: May be erratic or delayed</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: Relatively weak (to albumin [major] and other plasma constituents)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Primarily hepatic via glucuronidation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: 43% to 54% (nasal compared to 0.4 mg IM dose)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: IM, SubQ: 15 minutes; Intranasal: 19.8 to 30 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Neonates: Mean 3.1 &plusmn; 0.5 hours; Adults: IM, IV, or SubQ: 0.5 to 1.5 hours; Intranasal: ~2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (as metabolites)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1054274\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">For administration to neonates, it is no longer recommended to use a more dilute concentration (0.02 mg/mL [no longer commercially available]) and product has been discontinued. Use of this concentration results in unacceptably high fluid volumes, especially in small neonates. The 0.4 mg/mL preservative-free preparation should be used and can be accurately dosed with appropriately sized syringes (1 mL). </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Some products contain methyl and propylparabens. Naloxone has been used to increase blood pressure in patients with septic shock; increases in blood pressure may last several hours; however, an increase in patient survival has not been demonstrated and in some studies serious adverse effects (eg, agitation, pulmonary edema, hypotension, cardiac arrhythmias, seizures) have been reported; naloxone is generally not used for septic shock, especially in patients with underlying pain or opioid tolerance; optimal dosage for this indication has not been established; one neonatal study (n=2) reported a positive blood pressure response, but one neonate developed intractable seizures and died. <b>Note:</b> Naloxone is no longer a recommended adjunctive agent for the treatment of septic shock (SCCM [Dellinger 2013]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323451\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Liquid</b> (Narcan Nasal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4MG/0.1ML (1): $75.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Naloxone HCl Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.4 mg/mL (1 mL): $18.71</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg/10 mL (10 mL): $141.92</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Auto-injector</b> (Evzio Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.4 mg/0.4 mL (0.4 mL): $2,250.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg/0.4 mL (0.4 mL): $2,460.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Cartridge</b> (Naloxone HCl Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.4 mg/mL (1 mL): $18.53</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (Naloxone HCl Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg/2 mL (2 mL): $39.60</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199448\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Feng Du (CN);</li>\n      <li>Intrenon (CZ);</li>\n      <li>Jin Er Lun (CN);</li>\n      <li>Mapin (HK, MY);</li>\n      <li>Min-I-Jet Naloxone (GB);</li>\n      <li>N-Xone (LK);</li>\n      <li>Nalone (FR);</li>\n      <li>Naloxon (BG, CH, DE, IS);</li>\n      <li>Naloxone Hydrochlorid (GB);</li>\n      <li>Naloxonum Hydrochloricum (PL);</li>\n      <li>Naloxonum Prolongatum (PL);</li>\n      <li>Narcan (AE, AU, BE, BF, BH, BJ, BR, CI, CY, EG, ET, FR, GB, GH, GM, GN, GR, IL, IQ, IR, IT, JO, KE, KR, KW, LB, LR, LU, LY, MA, ML, MR, MU, MW, NE, NG, NZ, OM, PK, PL, QA, SA, SC, SD, SG, SL, SN, SY, TN, TW, TZ, UG, VE, YE, ZM, ZW);</li>\n      <li>Narcanti (AT, DK, HN, HU, MX, NO, PL, UY);</li>\n      <li>Narcotan (IN);</li>\n      <li>Narlox (PH);</li>\n      <li>Narxona (AR);</li>\n      <li>Naxone (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Nex (LK);</li>\n      <li>Nexodal (FI, IE, LT, NL, PT, SE, SI);</li>\n      <li>Opaxon (BD);</li>\n      <li>Oxogina (VE);</li>\n      <li>Prenoxad (GB);</li>\n      <li>Zynox (ZA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    ACOG Committee on Health Care for Underserved Women and American Society of Addiction Medicine. ACOG Committee opinion no. 524: opioid abuse, dependence, and addiction in pregnancy. <i>Obstet Gynecol</i>. 2012;119(5):1070-1076.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-pediatric-drug-information/abstract-text/22525931/pubmed\" target=\"_blank\" id=\"22525931\">22525931</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Albert S, Brason FW 2nd, Sanford CK, et al, &quot;Project Lazarus: Community-Based Overdose Prevention in Rural North Carolina,&quot; <i>Pain Med</i>, 2011, (12 Suppl 2):S77-85.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-pediatric-drug-information/abstract-text/21668761/pubmed\" target=\"_blank\" id=\"21668761\">21668761</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs, &quot;Naloxone Dosage and Route of Administration for Infants and Children: Addendum to Emergency Drug Doses for Infants and Children,&quot; <i>Pediatrics</i>, 1990, 86(3):484-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-pediatric-drug-information/abstract-text/2388800/pubmed\" target=\"_blank\" id=\"2388800\">2388800</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Pain Society (APS), <i>Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain</i>, 6th ed, Glenview, IL: 2008.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bailey B, &quot;Are There Teratogenic Risks Associated With Antidotes Used in the Acute Management of Poisoned Pregnant Women?&quot; <i>Birth Defects Res A Clin Mol Teratol</i>, 2003, 67(2):133-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-pediatric-drug-information/abstract-text/12769509/pubmed\" target=\"_blank\" id=\"12769509\">12769509</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Barton ED, Colwell CB, Wilfe T, Fosnocht D, Gravitz C, Bryan T, et al. Efficacy of intranasal naloxone as a needleless alternative for treatment of opioid overdose in the prehospital setting. <i>J Emerg Med</i>. 2005;29:265-271.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-pediatric-drug-information/abstract-text/16183444/pubmed\" target=\"_blank\" id=\"16183444\">16183444</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bennett AS, Bell A, Tomedi L, et al, &quot;Characteristics of an Overdose Prevention, Response, and Naloxone Distribution Program in Pittsburgh and Allegheny County, Pennsylvania,&quot;<i> J Urban Health</i>, 2011, 88(6):1020-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-pediatric-drug-information/abstract-text/21773877/pubmed\" target=\"_blank\" id=\"21773877\">21773877</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Boyer EW, &quot;Management of Opioid Analgesic Overdose,&quot; <i>N Engl J Med</i>, 2012, 367(2):146-55.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-pediatric-drug-information/abstract-text/22784117/pubmed\" target=\"_blank\" id=\"22784117\">22784117</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chamberlain JM and Klein BL, &ldquo;A Comprehensive Review of Naloxone for the Emergency Physician,&rdquo; <i>Am J Emerg Med</i>, 1994, 12(6):650-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-pediatric-drug-information/abstract-text/7945608 /pubmed\" target=\"_blank\" id=\"7945608 \">7945608 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dellinger RP, Levy MM, Rhodes A, et al, &ldquo;Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012,&rdquo; <i>Crit Care Med</i>, 2013, 41(2):580-637.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-pediatric-drug-information/abstract-text/23353941/pubmed\" target=\"_blank\" id=\"23353941\">23353941</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Doe-Simkins M, Walley AY, Epstein A, et al, &quot;Saved by the Nose: Bystander-Administered Intranasal Naloxone Hydrochloride for Opioid Overdose,&quot; <i>Am J Public Health</i>, 2009, 99(5):788-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-pediatric-drug-information/abstract-text/19363214/pubmed\" target=\"_blank\" id=\"19363214\">19363214</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dowling J, Isbister GK, Kirkpatrick CM, Naidoo D, Graudins A. Population pharmacokinetics of intravenous, intramuscular, and intranasal naloxone in human volunteers. <i>Ther Drug Monit</i>. 2008;30(4):490-496.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-pediatric-drug-information/abstract-text/18641540/pubmed\" target=\"_blank\" id=\"18641540\">18641540</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Doyon S. Chapter 180. <i>Opioids</i>. In: Tintinalli J, Stapczynski JS, Ma OJ, et al. <i>Tintinalli's Emergency Medicine</i>. 7th ed. New York, NY: McGraw-Hill; 2010.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Evzio 0.4 mg per 0.4 mL (naloxone hydrochloride) [prescribing information]. Richmond, VA: Kaleo; April 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Evzio 2 mg per 0.4 mL (naloxone hydrochloride) [prescribing information]. Richmond, VA: Kaleo; October 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Field JM, Hazinski MF, Sayre MR, et al, &quot;Part 1: Executive Summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&quot; <i>Circulation</i>, 2010, 122(18 Suppl 3):640-56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-pediatric-drug-information/abstract-text/20956217/pubmed\" target=\"_blank\" id=\"20956217\">20956217</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fischer CG and Cook DR, &quot;The Respiratory and Narcotic Antagonistic Effects of Naloxone in Infants,&quot; <i>Anesth Analg</i>, 1974, 53(6):849-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-pediatric-drug-information/abstract-text/4473926/pubmed\" target=\"_blank\" id=\"4473926\">4473926</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goldfrank L, Weisman RS, Errick JK, et al, &quot;A Dosing Nomogram for Continuous Infusion Intravenous Naloxone,&quot; <i>Ann Emerg Med</i>, 1986, 15(5):566-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-pediatric-drug-information/abstract-text/3963538/pubmed\" target=\"_blank\" id=\"3963538\">3963538</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gourlay GK and Coulthard K, &quot;The Role of Naloxone Infusions in the Treatment of Overdoses of Long Half-Life Narcotic Agonists: Application to Nor-methadone,&quot; <i>Br J Clin Pharmacol</i>, 1983, 15(2):269-71.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-pediatric-drug-information/abstract-text/6849762/pubmed\" target=\"_blank\" id=\"6849762\">6849762</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hegenbarth MA and American Academy of Pediatrics Committee on Drugs, &quot;Preparing for Pediatric Emergencies: Drugs to Consider,&quot; <i>Pediatrics</i>, 2008, 121(2):433-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-pediatric-drug-information/abstract-text/18245435/pubmed\" target=\"_blank\" id=\"18245435\">18245435</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kampman K, Jarvis M. American Society of Addiction Medicine (ASAM) national practice guideline for the use of medications in the treatment of addiction involving opioid use. J Addict Med. 2015;9(5):358-367. doi:10.1097/ADM.0000000000000166. http://www.asam.org/docs/default-source/practice-support/guidelines-and-consensus-docs/national-practice-guideline.pdf?sfvrsn=1826406300</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kattwinkel J, Perlman JM, Aziz K, et al, &quot;Part 15: Neonatal Resuscitation: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&quot; <i>Circulation</i>, 2010, 122(18 Suppl 3):909-19.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-pediatric-drug-information/abstract-text/20956231/pubmed\" target=\"_blank\" id=\"20956231\">20956231</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kelly AM, Kerr D, Dietze P, et al, &quot;Randomised Trial of Intranasal Versus Intramuscular Naloxone in Prehospital Treatment for Suspected Opioid Overdose,&quot; <i>Med J Aust</i>, 2005, 182(1):24-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-pediatric-drug-information/abstract-text/15651944/pubmed\" target=\"_blank\" id=\"15651944\">15651944</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kjellberg F and Tramer MR, &quot;Pharmacological Control of Opioid-Induced Pruritus: A Quantitative Systematic Review of Randomized Trials,&quot; <i>Eur J Anaesthesiol</i>, 2001, 18(6):346-57.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-pediatric-drug-information/abstract-text/11412287/pubmed\" target=\"_blank\" id=\"11412287\">11412287</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kleinman ME, Chameides L, Schexnayder SM, et al, &quot;Part 14: Pediatric Advanced Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&quot; <i>Circulation</i>, 2010, 122(18 Suppl 3):876-908.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-pediatric-drug-information/abstract-text/20956230 /pubmed\" target=\"_blank\" id=\"20956230 \">20956230 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lavonas EJ, Drennan IR, Gabrielli A, et al. Part 10: Special circumstances of resuscitation: 2015 American Heart Association Guidelines update for cardiopulmonary resuscitation and emergency cardiovascular care. <i>Circulation</i>. 2015;132(18 Suppl 2):S501-518.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-pediatric-drug-information/abstract-text/26472998/pubmed\" target=\"_blank\" id=\"26472998\">26472998</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lewis JM, Klein-Schwartz W, Benson BE, et al, &quot;Continuous Naloxone Infusion in Pediatric Narcotic Overdose,&quot; <i>Am J Dis Child</i>, 1984, 138(10):944-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-pediatric-drug-information/abstract-text/6475855/pubmed\" target=\"_blank\" id=\"6475855\">6475855</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Maxwell LG, Kaufmann SC, and Bitzer S, &quot;The Effects of a Small-Dose Naloxone Infusion on Opioid-Induced Side Effects and Analgesia in Children and Adolescents Treated With Intravenous Patient-controlled Analgesia: A Double-Blind, Prospective, Randomized, Controlled Study,&quot; <i>Anesth Analg</i>, 2005, 100(4):953-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-pediatric-drug-information/abstract-text/15781505/pubmed\" target=\"_blank\" id=\"15781505\">15781505</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mokhlesi B, Leikin JB, Murray P, et al, &ldquo;Adult Toxicology in Critical Care: Part II: Specific Poisonings,&rdquo; <i>Chest</i>, 2003, 123(3):897-922.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-pediatric-drug-information/abstract-text/12628894/pubmed\" target=\"_blank\" id=\"12628894\">12628894</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mycyk MB, Szyszko AL, and Aks SE, &quot;Nebulized Naloxone Gently and Effectively Reverses Methadone Intoxication,&quot; <i>J Emerg Med</i>, 2003, 24(2):185-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-pediatric-drug-information/abstract-text/12609650/pubmed\" target=\"_blank\" id=\"12609650\">12609650</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Naloxone hydrochloride injection [prescribing information]. Mendham, NJ: Somerset Therapeutics, LLC; December 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Narcan Nasal Spray (naloxone hydrochloride) [prescribing information]. Radnor, PA: Adapt Pharma; November 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Neumar RW, Otto CW, Link MS, et al, &quot;Part 8: Adult Advanced Cardiovascular Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&quot; <i>Circulation</i>, 2010, 122(18 Suppl 3):729-67.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-pediatric-drug-information/abstract-text/20956224/pubmed\" target=\"_blank\" id=\"20956224\">20956224</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Perry HE and Shannon MW, &quot;Diagnosis and Management of Opioid- and Benzodiazepine-Induced Comatose Overdose in Children,&quot; <i>Curr Opin Pediatr</i>, 1996, 8(3):243-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-pediatric-drug-information/abstract-text/8814402/pubmed\" target=\"_blank\" id=\"8814402\">8814402</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <i>Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain</i>. 6th ed. Glenview, IL: American Pain Society (APS); 2008.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Robertson TM, Hendey GW, Stroh G, et al, &quot;Intranasal Naloxone Is a Viable Alternative to Intravenous Naloxone for Prehospital Narcotic Overdose,&quot;<i> Prehosp Emerg Care</i>, 2009, 13(4):512-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-pediatric-drug-information/abstract-text/19731165/pubmed\" target=\"_blank\" id=\"19731165\">19731165</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Robinson A, Wermeling DP. Intranasal naloxone administration for treatment of opioid overdose. <i>Am J Health Syst Pharm</i>. 2014;71(24):2129-2135.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-pediatric-drug-information/abstract-text/25465584/pubmed\" target=\"_blank\" id=\"25465584\">25465584</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smith K, Hopp M, Mundin G, et al, &quot;Low Absolute Bioavailability of Oral Naloxone in Healthy Subjects,&quot;<i> Int J Clin Pharmacol Ther</i>, 2012, 50(5):360-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-pediatric-drug-information/abstract-text/22541841/pubmed\" target=\"_blank\" id=\"22541841\">22541841</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tenenbein M, &quot;Continuous Naloxone Infusion for Opiate Poisoning in Infancy,&quot; <i>J Pediatr</i>, 1984, 105(4):645-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-pediatric-drug-information/abstract-text/6481543/pubmed\" target=\"_blank\" id=\"6481543\">6481543</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vanden Hoek TL, Morrison LJ, Shuster M, et al, &quot;Part 12: Cardiac Arrest in Special Situations: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&quot; <i>Circulation</i>, 2010, 122(18 Suppl 3):829-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-pediatric-drug-information/abstract-text/20956228 /pubmed\" target=\"_blank\" id=\"20956228 \">20956228 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    van Vonderen JJ, Siew ML, Hooper SB, et al, &quot;Effects of Naloxone on the Breathing Pattern of a Newborn Exposed to Maternal Opiates,&quot; <i>Acta Paediatr</i>, 2012, 101(7):e309-12.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-pediatric-drug-information/abstract-text/22372574/pubmed\" target=\"_blank\" id=\"22372574\">22372574</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vrchoticky T, &ldquo;Naloxone for the Treatment of Narcotic Induced Pruritus,&rdquo; <i>Journal of Pediatric Pharmacy Practice</i>, 2000, 5(2):92-7.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Walley AY, Doe-Simkins M, Quinn E, Pierce C, Xuan Z, Ozonoff A. Opioid overdose prevention with intranasal naloxone among people who take methadone. <i>J Subst Abuse Treat</i>. 2013;44(2):241-247.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-pediatric-drug-information/abstract-text/22980450/pubmed\" target=\"_blank\" id=\"22980450\">22980450</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wampler DA, Molina DK, McManus J, et al, &quot;No Deaths Associated With Patient Refusal of Transport After Naloxone-Reversed Opioid Overdose,&quot; <i>Prehosp Emerg Care</i>, 2011, 15(3):320-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-pediatric-drug-information/abstract-text/21612385/pubmed\" target=\"_blank\" id=\"21612385\">21612385</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weber JM, Tataris KL, Hoffman JD, et al, &quot;Can Nebulized Naloxone Be Used Safely and Effectively by Emergency Medical Services for Suspected Opioid Overdose,&quot; <i>Prehosp Emerg Care</i>, 2012, 16(2):289-92.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-pediatric-drug-information/abstract-text/22191727/pubmed\" target=\"_blank\" id=\"22191727\">22191727</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12628 Version 153.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Special Alerts\" href=\"#F50353046\" class=\"outlineLink\">Special Alerts</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F25063978\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F2980444\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1054265\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11443895\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1054259\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F199436\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F199421\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1054269\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F199454\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1054268\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F199507\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F199504\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F199443\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F199425\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299739\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F199430\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F199432\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F199446\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1054264\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F199424\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F199442\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F1054274\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323451\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F199448\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12628|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=naloxone-drug-information\" class=\"drug drug_general\">Naloxone: Drug information</a></li><li><a href=\"topic.htm?path=naloxone-patient-drug-information\" class=\"drug drug_patient\">Naloxone: Patient drug information</a></li></ul></div></div>","javascript":null}